𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients

✍ Scribed by Allen R. Nissenson; Suzanne K. Swan; Jill S. Lindberg; Steven D. Soroka; Robert Beatey; Chao Wang; Nancy Picarello; Anna McDermott-Vitak; Bradley J. Maroni

Book ID
114463685
Publisher
Elsevier Science
Year
2002
Tongue
English
Weight
103 KB
Volume
40
Category
Article
ISSN
0272-6386

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Randomized trial of darbepoetin alfa for
Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients
✍ Vanrenterghem, Yves; BÑrÑny, Peter; Mann, Johannes F.E.; Kerr, Peter G.; Wilso πŸ“‚ Article πŸ“… 2002 πŸ› Nature Publishing Group 🌐 English βš– 601 KB

## Background: Darbepoetin alfa is a glycoprotein with a three-fold longer terminal half-life than recombinant human erythropoietin (rhuepo). we aimed to determine whether darbepoetin alfa is as effective and well tolerated as rhuepo for treating renal anemia in dialysis patients when administered

A randomized, active-control, pilot tria
A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease
✍ John A. Glaspy; Jaswant Sinh Jadeja; Glen Justice; Alex Fleishman; Gregory Rossi πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 123 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Anemia in patients receiving chemotherapy can be ameliorated with recombinant human erythropoietin (rHuEPO), which is administered one to three times per week. Darbepoetin Ξ±, a new erythropoietic agent, has longer serum residence time, allowing it to be administered less